Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Menarini Owners Acquitted Of Fraud

Executive Summary

Lucia and Giovanni Aleotti have been cleared of fraud against the Italian health system, and will continue to lead the Florentine company transformed into a major multinational by their father.

You may also be interested in...



Business As Usual For Menarini Despite Managing Siblings’ Fraud Sentence

Siblings Lucia and Alberto Giovanni Aleotti, respectively president and vice-president of Italian pharmaceutical company Menarini, have been sentenced for tax fraud by a court in Florence. Lucia Aleotti has resigned from the board of Farmindustria, Italy’s industry association, but its president Massimo Scaccabarozzi declared his expectation that they would be cleared on appeal. The case is far from closed.

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

20 Voices: What Does 2024 Hold For Biopharma?

20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC124313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel